Personalised mental healthcare at scale.
Discover what makes Mobio Interactive unique.
It is exceptionally difficult to deliver precision psychiatry at scale.
MI combines computer vision, AI and clinically validate psychotherapy, in a single, easy-to-use mobile platform.
Personalisation of mental healthcare via real time measurement of therapy efficacy with a validated digital biomarker of stress.
This solution is 100% MI IP, scales and integrates seamlessly into clinicians’ pre-existing workflows.
Platform licensing to hospitals and payors establishes the critical infrastructure and ease of use that supports rapid prescription and adoption of regulated Class II SaMD interventions.
*Al-Jebrni et al., AI-enabled remote and objective quantification of stress at scale. BSPC 2020
MI is rapidly approaching its next inflection point: FDA clearance. When this comes to pass, valuation will increase and new capital will be raised. Pre A investors guarantee FDA clearance.Globally, more than 1 in 10 people need mental health therapy. Digital therapies for mental illness will reach $500 billion/yr by 2035. As an early leader, MI aims to capture 10% of this market opportunity as the first in history to achieve precision psychiatry at scale.
Effective and accessible healthcare for every human.